Figure 4

Changes in analyte concentrations after infliximab treatment. The serum concentrations of the indicated analytes at the 24-week timepoint for placebo and 3 and 5 mg/kg infliximab treatment groups in the T54 COPD cohort are shown as signed-fold over respective baseline concentrations. Data presented as box (median, interquartile range) and whiskers (10^th-90^th percentiles). *p < 0.05 for placebo vs 3 and 5 mg/kg infliximab groups combined; † p < 0.05 for 5 mg/kg infliximab group vs placebo. IL, interleukin; IGF-1, insulin-like growth factor-1; CRP, C-reactive protein.